E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Cannabinoid Signaling in Nervous System"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry, Molecular Biology and Biophysics".

Deadline for manuscript submissions: 20 May 2017

Special Issue Editors

Guest Editor
Prof. Dr. Daniela Parolaro

Department of Biotechnology and Life Sciences, and Neuroscience Center, University of Insubria, Busto Arsizi, Italy
Website | E-Mail
Interests: endocannabinoisd system; adolescence; psychiatric disorders; autism
Guest Editor
Prof. Dr. Tiziana Rubino

Department of Biotechnology and Life Sciences, and Neuroscience Center, University of Insubria, Busto Arsizi, Italy
Website | E-Mail
Interests: endocannabinoisd system; adolescence; psychiatric disorders; epigenetics

Special Issue Information

Dear Colleagues,

The discovery in 1990 that the effects of delta-9 tetrahydrocannabinol (THC), the main psychoactive component present in Cannabis sativa, were mediated by its interaction with a specific receptor, represented the starting point for the characterization of what is now called the endocannabinoid system (ECS).

The initial picture showed that the ECS comprised two main receptors, CB1 and CB2, the endocannabinoids (the best known are anandamide and 2-arachidonoylglycerol) as well as the enzymes responsible for their synthesis and degradation. In the last few years, additional receptors and enzymes have been discovered, adding complexity to the system. In the meantime, growing evidence indicates that dysregulation of the ECS plays a key role in several pathologies of the nervous system, thus opening the way to the possibility of targeting ECS for therapeutic purposes.

Therefore, this Special Issue will provide an updated knowledge of both the physiology of the ECS signaling and its involvement in the neurobiology of several disorders of the nervous system.

Prof. Dr. Daniela Parolaro
Prof. Dr. Tiziana Rubino
Guest Editors

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs).

 

Keywords

  • cannabinoid receptors
  • endocannabinoids
  • CNS development
  • epigenetics
  • emotionality
  • autism spectrum disorder
  • neurodegenerative diseases
  • psychosis
  • addiction
  • sex differences

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease
Int. J. Mol. Sci. 2017, 18(4), 684; doi:10.3390/ijms18040684
Received: 22 February 2017 / Revised: 15 March 2017 / Accepted: 17 March 2017 / Published: 23 March 2017
PDF Full-text (1000 KB) | HTML Full-text | XML Full-text
Abstract
Several cannabinoids afforded neuroprotection in experimental models of Huntington’s disease (HD). We investigated whether a 1:1 combination of botanical extracts enriched in either ∆9-tetrahydrocannabinol (∆9-THC) or cannabidiol (CBD), which are the main constituents of the cannabis-based medicine Sativex®
[...] Read more.
Several cannabinoids afforded neuroprotection in experimental models of Huntington’s disease (HD). We investigated whether a 1:1 combination of botanical extracts enriched in either ∆9-tetrahydrocannabinol (∆9-THC) or cannabidiol (CBD), which are the main constituents of the cannabis-based medicine Sativex®, is beneficial in R6/2 mice (a transgenic model of HD), as it was previously shown to have positive effects in neurotoxin-based models of HD. We recorded the progression of neurological deficits and the extent of striatal deterioration, using behavioral, in vivo imaging, and biochemical methods in R6/2 mice and their corresponding wild-type mice. The mice were daily treated, starting at 4 weeks after birth, with a Sativex-like combination of phytocannabinoids (equivalent to 3 mg/kg weight of pure CBD + ∆9-THC) or vehicle. R6/2 mice exhibited the characteristic deterioration in rotarod performance that initiated at 6 weeks and progressed up to 10 weeks, and elevated clasping behavior reflecting dystonia. Treatment with the Sativex-like combination of phytocannabinoids did not recover rotarod performance, but markedly attenuated clasping behavior. The in vivo positron emission tomography (PET) analysis of R6/2 animals at 10 weeks revealed a reduced metabolic activity in the basal ganglia, which was partially attenuated by treatment with the Sativex-like combination of phytocannabinoids. Proton nuclear magnetic resonance spectroscopy (H+-MRS) analysis of the ex vivo striatum of R6/2 mice at 12 weeks revealed changes in various prognostic markers reflecting events typically found in HD patients and animal models, such as energy failure, mitochondrial dysfunction, and excitotoxicity. Some of these changes (taurine/creatine, taurine/N-acetylaspartate, and N-acetylaspartate/choline ratios) were completely reversed by treatment with the Sativex-like combination of phytocannabinoids. A Sativex-like combination of phytocannabinoids administered to R6/2 mice at the onset of motor symptoms produced certain benefits on the progression of striatal deterioration in these mice, which supports the interest of this cannabinoid-based medicine for the treatment of disease progression in HD patients. Full article
(This article belongs to the Special Issue Cannabinoid Signaling in Nervous System)
Figures

Journal Contact

MDPI AG
IJMS Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
E-Mail: 
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Special Issue Edit a special issue Review for IJMS
Back to Top